NCT02815059 is a Phase 1 clinical trial of Ibrutinib in Acute Lymphoblastic Leukemia, sponsored by University of Utah.

Who is sponsoring NCT02815059?

NCT02815059 is sponsored by University of Utah.

What drugs are being tested in NCT02815059?

Interventions in NCT02815059: Ibrutinib, Dasatinib, Prednisone.

What condition does NCT02815059 study?

NCT02815059 studies Acute Lymphoblastic Leukemia.

Is NCT02815059 still recruiting?

NCT02815059 is currently withdrawn. Last updated 31 January 2018.

Last reviewed 2018-01-31 · How we verify

NCT02815059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Withdrawn Phase 1 Last updated 31 January 2018

What this trial tests

Phase 1 trial testing Ibrutinib in Acute Lymphoblastic Leukemia. Withdrawn.

Timeline

28 September 2016

Primary endpoint
9 January 2018

9 January 2018

Quick facts

Lead sponsor	University of Utah
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	28 September 2016
Primary completion	9 January 2018
Estimated completion	9 January 2018
Sites	1 location across United States

Drugs / interventions tested

Ibrutinib (ibrutinib) — full drug profile →
Dasatinib (dasatinib) — full drug profile →
Prednisone (prednisone) — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →

Sponsor

University of Utah

Who can join

60 and older, any sex, with Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges.
Soverini S, Bassan R, Lion T. · · 2019 · cited 83× · PMID 31014376 · DOI 10.1186/s13045-019-0729-2

Verify or expand the search:

Other trials of Ibrutinib

Trials testing the same drug.

NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
NCT06649812 — Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress · Phase 2 · recruiting
NCT07169565 — Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · Phase 1 · not yet recruiting
NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting

Other recruiting trials for Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02815059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 31 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02815059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing